Novo Holdings announced on Saturday that all regulatory conditions for its $16.5 billion acquisition of U.S. drug manufacturer Catalent have been met, with the transaction set to finalize in the coming days.
The deal, first agreed upon in February, aims to enhance production of the weight-loss drug Wegovy. As part of the agreement, Novo Holdings will sell three of Catalent’s factories—located in Italy, Belgium, and the United States—to Novo Nordisk for $11 billion. These facilities specialize in filling injection pens under sterile conditions.